United States Patent 10,195,175 (US 10,195,175) ADC + Checkpoint-Inhibitor Post-Checkpoint Failure: Claim-Level Validity, Claim Construction Risks, and Landscape

What does US 10,195,175 claim, in operational terms?

US 10,195,175 claims a sequence-defined cancer treatment regimen:

Administer sacituzumab govitecan (Trop-2 ADC) to a subject with cancer.
Administer at least one checkpoint inhibitor after the subject has failed to respond to therapy with a checkpoint inhibitor.
The ADC identity is fixed to Trop-2 antibody conjugated to SN-38, where the ADC is sacituzumab govitecan.
Dependent claims add dose windows, response/tumor reduction thresholds, metastatic framing, and broad “additional modalities.”

Core claim logic (Claim 1)

Claim 1 is not a general combination of ADC plus checkpoint inhibitor. It is a rescue-after-failure combination:

ADC: sacituzumab govitecan
Checkpoint inhibitor: any listed checkpoint inhibitor (dependent claim set)
Timing/condition: “subject has failed to respond to therapy with a checkpoint inhibitor, prior to treatment with the ADC”
Purpose/observable outcome: not explicitly required in claim 1, but used in dependent claims (size reduction targets).

Dependent claim feature map (high-leverage for validity)

Claim	Added limitation	Practical effect on infringement proof
2	Checkpoint inhibitor species list includes ipilimumab, nivolumab, pembrolizumab, etc.	Expands “where to look” for prescribing data; reduces novelty escape by picking another PD-1/CTLA-4 agent
3	ADC dose range 4 to 16 mg/kg	Narrower than Claim 1; relevant for label-compliant vs noncompliant dosing
4	ADC dose range 8 to 10 mg/kg	Further narrows; closer to common clinical dosing patterns for sacituzumab govitecan
5	Selected doses 6, 8, 9, 10, 12 mg/kg	Discrete infringement “sweet spots”
6	Solid tumor with tumor reduction thresholds ≥15/20/30/40%	Ties to RECIST-type endpoints; raises evidentiary burden and can create design-around via not meeting the thresholds
7-8	Metastatic framing; further reduces/eliminates metastases	Metastatic status may be inherent for many ADC populations; “eliminating metastases” is outcome-based
9-10	Additional modality list is extremely broad; includes chemotherapy, targeted therapy, peptides, cytokines, radiation, surgery, gene therapy, RNAi	Makes combination “cover all” and can help capture real-world regimens, but also creates obviousness vulnerability because it reads like a standard add-on list
11-12	Tumor type lists	Helps with enforceability by mapping to specific indications; also increases prior-art matching opportunities

How do these claims interact with sacituzumab govitecan’s known profile?

Sacituzumab govitecan is established as:

Trop-2 targeting
SN-38 payload
ADC platform with published clinical activity across multiple solid tumors

The patent’s novelty, if any, must come from (i) sequencing and (ii) the specific combination concept framed as post-checkpoint failure rather than the ADC itself.

Because the ADC is fixed to sacituzumab govitecan, the claim attempts to avoid broad ADC prior art by narrowing to:

the antigen (Trop-2),
the payload (SN-38),
the product identity (sacituzumab govitecan).

That narrowing matters for infringement, but it does not automatically cure validity. A prior art reference that already discloses sacituzumab govitecan + checkpoint inhibitor (even if not in the exact post-failure sequence) can still be used to challenge novelty or render the “sequencing” an obvious design choice depending on what the reference teaches about checkpoint resistance and subsequent lines.

What is the key validity battleground for Claim 1?

1) Is “checkpoint-inhibitor failure prior to ADC” a technical distinction or a mere intended use?

Claim 1 includes: “subject has failed to respond to therapy with a checkpoint inhibitor, prior to treatment with the ADC.”

That can be attacked as:

Condition precedent that does not change the biochemical or mechanistic combination,
A line-of-therapy statement that may be treated as an “intended use” or “data generation/selection” limitation unless it changes what is administered or how.

From an examiner or court perspective, the most relevant question becomes whether the prior art teaches the same sequencing logic. If the combination is known and the patient selection is “checkpoint-refractory,” then the claim may fail for novelty or be obvious as an expected application.

2) Is the checkpoint inhibitor timing itself taught?

If earlier disclosures combine sacituzumab govitecan with PD-1/PD-L1 or CTLA-4 agents in patients progressing on checkpoint therapy, then the patent can be directly anticipated.

If earlier disclosures only show:

concurrent combination or
checkpoint inhibitor earlier in therapy, then this claim still can be obvious if the prior art provides a rationale that ADCs can re-engage immune response or that checkpoint-refractory populations are an expected next cohort for combination trials.

3) Does the claim overreach through breadth in “at least one checkpoint inhibitor”?

Dependent claim 2 enumerates multiple checkpoint inhibitors. If a prior art reference discloses one (e.g., pembrolizumab) with sacituzumab govitecan, the generic mapping to “at least one checkpoint inhibitor” can remain within Claim 1’s scope under claim construction (depending on whether the court treats Claim 1 as generic and Claim 2 as narrowing only for certain embodiments).

That structure can create:

stronger infringement reach,
but weaker defensibility against combinations that exist with any of the listed checkpoint inhibitors.

How strong are dependent claim limitations as novelty or patentability hooks?

Dose-range dependent claims (3-5)

The dose windows are moderately narrow:

4 to 16 mg/kg (Claim 3)
8 to 10 mg/kg (Claim 4)
selected discrete doses 6/8/9/10/12 mg/kg (Claim 5)

In a crowded landscape, these may still be anticipated or made obvious if:

prior sacituzumab govitecan studies use these doses (as they typically do), and
those studies include checkpoint inhibitor co-administration in the same post-checkpoint failure context.

However, dose-range claims can sometimes preserve validity if:

checkpoint combination prior art uses a different dose,
or teaches dose escalation/selection away from these values.

Tumor reduction thresholds (Claim 6)

Outcome-based thresholds are often a weak hook for validity because:

they can be treated as result-oriented and not necessarily limiting to method steps,
they depend on clinical endpoint measurement methods (RECIST vs other),
they invite arguments that prior art could generate such results without predicting them.

Yet they can matter for enforcement and design-around: if a regimen does not reliably achieve the specified reduction categories, it may avoid infringement under a strict “results required” interpretation.

Tumor type lists (Claims 11-12)

These do two things:

They improve practical enforcement by targeting commercially relevant indications.
They also increase prior-art matching because broad solid tumor ADC literature and checkpoint literature have extensive overlap.

Tumor lists rarely provide a strong novelty anchor unless a particular indication or subtype is uniquely tied to the combination sequence and yields unexpected technical results.

Broad add-on modality list (Claims 9-10)

Claim 9’s “one or more additional therapeutic modalities” list is extremely broad, including virtually standard oncology treatments. That breadth increases enforceability in the abstract, but it can also be used against patentability:

If add-on therapy is conventional and taught,
then the “additional modalities” limitation may be viewed as routine optimization rather than a patentable invention.

What does “checkpoint inhibitor + sacituzumab govitecan” likely look like in the prior-art pattern?

Even without mapping to specific documents here, the landscape structure for ADC + checkpoint inhibition in the US is typically dominated by combinations that fall into these buckets:

ADC + PD-1/PD-L1 or CTLA-4 across solid tumors
Trials enrolling checkpoint-refractory populations
Post-failure sequencing studies where the prior checkpoint agent is included as background or as inclusion criteria

US 10,195,175 attempts to isolate a specific combination: sacituzumab govitecan plus checkpoint inhibitors in a checkpoint-failed before ADC population.

If earlier trials of sacituzumab govitecan with PD-1/PD-L1 agents already enrolled “progressed on checkpoint inhibitor” cohorts, then the patent is exposed to anticipation/obviousness arguments that the sequencing is not novel.

If the earlier trials were not in checkpoint-refractory cohorts, validity depends on whether the prior art provides a teaching to move sacituzumab govitecan into that cohort after checkpoint failure.

Claim construction pressure points (where enforceability can break)

1) What does “failed to respond” mean operationally?

This phrase can create disputes about:

whether “failure to respond” includes partial response followed by progression,
whether “no objective response” vs “progression” qualifies,
whether stable disease counts,
and whether the definition changes across checkpoint agent labels.

Courts often require a measurable clinical definition, which can tighten the factual basis for infringement.

2) Does Claim 1 require the checkpoint inhibitor to be administered after failure, or just to be administered at some point?

Claim 1 says checkpoint inhibitor administration happens in a sequence where the subject has “failed to respond… prior to treatment with the ADC.” That indicates:

checkpoint inhibitor is administered after failure, and
the ADC is administered after that failure.

But the claim does not tightly specify a “run-in” vs “washout.” That can broaden infringement if clinicians do not maintain a long interval.

3) Does “administering to the subject… at least one checkpoint inhibitor” require ongoing dosing during ADC?

Claim 1 reads as combination therapy where checkpoint inhibitor is administered to the subject. It does not explicitly require concomitance with ADC dosing, only sequence conditioned on prior failure.

That can expand enforcement if a checkpoint inhibitor is continued or restarted around ADC.

Landscape implications for investors and business planning

Where the patent’s commercial value is most sensitive

US 10,195,175 is most enforceable (and most valuable) where real-world practice matches all of these elements simultaneously:

Sacituzumab govitecan used in a solid tumor setting
Patient has progressed on a checkpoint inhibitor
A checkpoint inhibitor is used in the regimen after that progression
Dosing aligns with the claim dose windows if relying on dependent claims

Because the patent has a strong “sequence-conditioned” centerpiece, its practical value tracks:

clinical trial inclusion criteria and
whether post-checkpoint continuation or combination is standard-of-care in the relevant tumor types.

Where it is most vulnerable

The patent is most exposed to invalidity where prior art shows:

sacituzumab govitecan with PD-1/PD-L1 or CTLA-4,
in checkpoint-refractory patients,
using doses within typical ranges.

It is also vulnerable if the prior art frames checkpoint-refractory selection as routine and expects ADCs to be tested post-checkpoint failure without needing a unique inventive step.

Key Takeaways

US 10,195,175 fixes the ADC to sacituzumab govitecan (anti-Trop-2-SN-38) and makes checkpoint-failure before ADC the core distinguishing feature in Claim 1.
The claim’s strongest operational elements are sequence-conditioned patient selection and checkpoint inhibitor inclusion; the ADC identity is narrowed, but that alone does not protect against anticipation/obviousness if combinations were already tested in checkpoint-refractory cohorts.
Dependent claims on dose ranges can preserve patentability if prior art uses materially different dosing for the combination context; tumor response thresholds are more likely to face “result-oriented” scrutiny and typically have higher evidentiary burden.
The broad “additional modalities” section increases practical reach but also increases obviousness risk by reading like routine add-on therapy.
Enforceability is likely to hinge on how “failed to respond” is defined clinically and whether practice matches the sequence implied by Claim 1.

FAQs

1) Is Claim 1 limited to concurrent administration of checkpoint inhibitor and sacituzumab govitecan?

Not explicitly. Claim 1 requires checkpoint inhibitor administration and that checkpoint failure occurs prior to ADC treatment, but it does not state concomitance with a fixed overlap period.

2) Does dependent claim 2 reduce risk for generic PD-(L)1 vs CTLA-4 switches?

It reduces ambiguity by listing agents, but Claim 1 itself is broadly framed. If a court construes Claim 1 generically, the listed alternatives in Claim 2 may not fully constrain the combination landscape.

3) Can prior art invalidate the patent even if it uses checkpoint inhibitor earlier in the treatment sequence?

Yes, if it teaches or makes obvious the post-checkpoint-failure sequencing as the next step for the same combination concept.

4) Are the tumor size reduction thresholds strong novelty hooks?

They are likely weaker for patentability than they appear because they are outcome-driven. They can matter for infringement proof, depending on how the court treats result limitations.

5) What is the highest-value dependent claim for commercial freedom-to-operate?

Typically the dose-dependent claims (3-5) because they allow a narrower factual match. If a competitor uses a different sacituzumab govitecan dose outside 4 to 16 mg/kg or outside the selected discrete doses, those dependent claims may be avoided even if Claim 1 is still asserted.

References

[1] United States Patent 10,195,175 (claims as provided in the prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978	10,195,175	2037-04-06
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	March 25, 2011	10,195,175	2037-04-06
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	September 04, 2014	10,195,175	2037-04-06
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	Injection	125514	January 15, 2015	10,195,175	2037-04-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,195,175

Summary for Patent: 10,195,175